ZYMOGENETICS
ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.
ZYMOGENETICS
Social Links:
Industry:
Therapeutics
Founded:
1981-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.zymogenetics.com
Total Employee:
251+
Status:
Closed
Contact:
(206)442-6600
Total Funding:
197 M USD
Technology used in webpage:
Bristol Myers Squibb
Similar Organizations
Lannett Company
Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.
Neumedicines
Neumedicines is a biotechnology company that focuses on the development of protein therapeutics.
Current Employees Featured
Founder
Stock Details
Investors List
Deerfield
Deerfield investment in Post-IPO Debt - ZymoGenetics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Funding Round - ZymoGenetics
Official Site Inspections
http://www.zymogenetics.com
- Host name: 165.89.235.20
- IP address: 165.89.235.20
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "ZymoGenetics"
ZymoGenetics - Crunchbase Company Profile & Funding
ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a …See details»
Organization | ZymoGenetics
ZymoGenetics Report issue. Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4. Founded: Seattle WA United States ... Organization Overview. First Clinical Trial. 2004 …See details»
ZymoGenetics Company Profile 2024: Valuation, …
ZymoGenetics was founded in 1981. Where is ZymoGenetics headquartered? ZymoGenetics is headquartered in Seattle, WA. What is the size of ZymoGenetics? ZymoGenetics has 323 total employees. What industry is …See details»
Zymogenetics, Inc. Company Profile | Seattle, WA | Competitors ...
Company Description: ZymoGenetics has proteins on its plate. The firm culls genomics databases to identify and develop protein-based drugs targeting a variety conditions. Its sole …See details»
Bristol-Myers Squibb will close its Seattle …
Nov 1, 2018 Zymogenetics was founded in 1981 in Seattle and was acquired by Bristol-Myers Squibb in 2010 for $885 million. The company has been winding down its Seattle operations for some time.See details»
ZymoGenetics - businessabc.net
Nov 4, 2024 ZymoGenetics is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies that improve patient health. Our …See details»
ZymoGenetics - Funding, Financials, Valuation & Investors
ZymoGenetics is registered under the ticker NASDAQ:ZGEN . Their stock opened with $12.00 in its Feb 1, 2002 IPO. Stock Symbol NASDAQ:ZGEN ; Valuation at IPO $540M; Money Raised …See details»
Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.
Oct 12, 2010 Bristol-Myers Squibb initiated on September 10, 2010, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics for $9.75 per share.See details»
ZymoGenetics - Contacts, Employees, Board Members, Advisors
ZymoGenetics’ early focus on the development of production systems for recombinant proteinsSee details»
Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.
Oct 12, 2010 Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has completed its previously announced acquisition of ZymoGenetics, Inc. (NASDAQ: ZGEN). As …See details»
Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.
As a result of the transaction, ZymoGenetics has become a wholly-owned subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb initiated on September 10, 2010, a cash tender offer to …See details»
Bristol-Myers Squibb to Acquire ZymoGenetics
Sep 7, 2010 Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) announced today that the companies have signed a definitive agreement providing for …See details»
BMS forges $885M deal to buy ZymoGenetics
Sep 8, 2010 Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million, snaring its development partner on a mid-stage hepatitis C program along with a …See details»
Zymogenetics Inc. - The New York Times
One of them, the fast-growing ZymoGenetics, planning to expand its biomedical research, is spending $25 million to restore the landmark Lake Union Steam Plant, Seattle City Light's first ...See details»
ZymoGenetics' moves recall young Genentech - Nature
Sep 3, 2007 ZymoGenetics remained a subsidiary of Novo Nordisk before being spun out in 2000. Since then, the companies have maintained a close partnership, and Novo owns about …See details»
ZymoGenetics: Chemistry & Biology - Cell Press
Drug Discovery: For most, the expression conjures up thoughts of big pharma and the hunt for “small-molecule drugs” to treat cancer and other human diseases. And rightly so; this is big …See details»
ZymoGenetics - Cell Press
ZymoGenetics A Quiet Powerhouse Emerges portion of the expense in the drug E. coli. The relationship grew, and discovery process comes relatively ZymoGenetics was soon absorbed …See details»
Bristol-Myers Squibb to Acquire ZymoGenetics | Fierce Pharma
Sep 7, 2010 NEW YORK & SEATTLE--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that the companies …See details»
Unusual zymogen activation patterns in the protein corona of Ca ...
Jul 22, 2021 Zeolites are promising materials to prevent serious blood loss and death from haemorrhagic shocks, but their mode of action to initiate blood clotting remained vague. Now, …See details»